What does YAPHARM do?

YAPHARM is a pharmacy in Ukkel. Private Limited, started on 18 August 2020, 1 establishment.

What is the address of YAPHARM?

The registered office of YAPHARM is located at Gabriellestraat 44, 1180 Ukkel.

Is YAPHARM still active?

Yes. According to the CBE (31 October 2026) YAPHARM is active, legal situation “Normale toestand”, started on 18 August 2020.

Is YAPHARM registered on Peppol?

Yes, YAPHARM is registered on the Peppol network with ID 0208:0752712377.

What is the enterprise number of YAPHARM?

The enterprise number of YAPHARM is BE0752712377.

When was YAPHARM founded?

YAPHARM was founded on 18 August 2020.

Who are the directors of YAPHARM?

According to the 2025 annual accounts, the directors of YAPHARM are: Yassine Aikar.

Is YAPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 August 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did YAPHARM make in 2025?

YAPHARM posted a profit after taxes of € 41,299 in financial year 2025.

What is the revenue of YAPHARM?

As a small company, YAPHARM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 54,364.

YAPHARM (Private Limited) - Ukkel - BE0752712377

Dossier YAPHARM, printed on 31 October 2026 from databakkes.be/en/0752712377/yapharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

YAPHARM from Ukkel, company number BE0752712377, closed financial year 2025 with a result of € 41,299 after tax. For that financial year YAPHARM recorded a gross margin of € 54,364 and equity of € 158,159. Compared with financial year 2024, the result moved from € -5,919 to € 41,299. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 158,159

▲ 35% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 41,299

▲ still € 5,919 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 8,405

▼ 76% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 156,159.

People and assets in 2025

Vehicles and equipment

€ 97

▼ 91% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 255,332

▲ € 254,712 vs 2024

€ 24,521 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 1,517

▲ 14% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 21,200

▲ € 18,864 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 117,818 Gross margin 2022: € 117,818 First fiscal year in the series	€ 4,018 Gross margin 2023: € 4,018 ▼ 97% vs 2022 (€ 117,818) Unfavourable step	€ -9,235 Gross margin 2024: € -9,235 ▼ € 13,253 vs 2023 (€ 4,018) Unfavourable step	€ 54,364 Gross margin 2025: € 54,364 ▲ € 63,598 vs 2024 (€ -9,235) Favourable step	▲ € 63,598
Profit after taxes	€ 91,373 Profit after taxes 2022: € 91,373 First fiscal year in the series	€ -4,138 Profit after taxes 2023: € -4,138 ▼ € 95,510 vs 2022 (€ 91,373) Unfavourable step	€ -5,919 Profit after taxes 2024: € -5,919 ▼ € 1,781 vs 2023 (€ -4,138) Unfavourable step	€ 41,299 Profit after taxes 2025: € 41,299 ▲ € 47,218 vs 2024 (€ -5,919) Favourable step	▲ € 47,218
Equity	€ 126,916 Equity 2022: € 126,916 First fiscal year in the series	€ 122,779 Equity 2023: € 122,779 ▼ 3% vs 2022 (€ 126,916) Unfavourable step	€ 116,860 Equity 2024: € 116,860 ▼ 5% vs 2023 (€ 122,779) Unfavourable step	€ 158,159 Equity 2025: € 158,159 ▲ 35% vs 2024 (€ 116,860) Favourable step	▲ 35%
Total debts	€ 60,688 Total debts 2022: € 60,688 First fiscal year in the series	€ 41,397 Total debts 2023: € 41,397 ▼ 32% vs 2022 (€ 60,688) Favourable step	€ 298,247 Total debts 2024: € 298,247 ▲ € 256,851 vs 2023 (€ 41,397) Unfavourable step	€ 278,068 Total debts 2025: € 278,068 ▼ 7% vs 2024 (€ 298,247) Favourable step	▼ 7%
Cash	€ 117,483 Cash 2022: € 117,483 First fiscal year in the series	€ 79,538 Cash 2023: € 79,538 ▼ 32% vs 2022 (€ 117,483) Unfavourable step	€ 35,658 Cash 2024: € 35,658 ▼ 55% vs 2023 (€ 79,538) Unfavourable step	€ 8,405 Cash 2025: € 8,405 ▼ 76% vs 2024 (€ 35,658) Unfavourable step	▼ 76%
Retained profit	€ 124,916 Retained profit 2022: € 124,916 First fiscal year in the series	€ 120,779 Retained profit 2023: € 120,779 ▼ 3% vs 2022 (€ 124,916) Unfavourable step	€ 114,860 Retained profit 2024: € 114,860 ▼ 5% vs 2023 (€ 120,779) Unfavourable step	€ 156,159 Retained profit 2025: € 156,159 ▲ 36% vs 2024 (€ 114,860) Favourable step	▲ 36%
Dividend	€ 10,000 Dividend 2022: € 10,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 10,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 8,010 Bank debt 2022: € 8,010 First fiscal year in the series	€ 4,327 Bank debt 2023: € 4,327 ▼ 46% vs 2022 (€ 8,010) Favourable step	€ 620 Bank debt 2024: € 620 ▼ 86% vs 2023 (€ 4,327) Favourable step	€ 255,332 Bank debt 2025: € 255,332 ▲ € 254,712 vs 2024 (€ 620) Unfavourable step	▲ € 254,712
Balance sheet total	€ 187,604 Balance sheet total 2022: € 187,604 First fiscal year in the series	€ 164,175 Balance sheet total 2023: € 164,175 ▼ 12% vs 2022 (€ 187,604) Unchanged	€ 415,107 Balance sheet total 2024: € 415,107 ▲ 153% vs 2023 (€ 164,175) Unchanged	€ 436,227 Balance sheet total 2025: € 436,227 ▲ 5% vs 2024 (€ 415,107) Unchanged	▲ 5%

Key figures of YAPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to YAPHARM?

What happened at YAPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 41,299. filed late Source: NBB ↗
Aug 18, 2020 New establishment in Dilbeek. KBO
Aug 18, 2020 Start of the company according to the CBE. KBO

In short

From € 91,373 profit in 2022 to € 41,299 profit in 2025.

Paid € 33,502 in corporate taxes since 2022.

Best year ever: 2022, with € 91,373 profit.

Paid out € 10,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Yassine Aikar

YAPHARM

Pharmacie Saint-Guidon 100%

Behind YAPHARM is Yassine Aikar. It owns 100% of Pharmacie Saint-Guidon itself.

Directors

According to the 2025 annual accounts

Yassine Aikar

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Gabriellestraat 44

1180 Ukkel

2.308.438.662

Hoogveldlaan 38

1700 Dilbeek

Active since 18 August 2020

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0752.712.377
VAT number: BE 0752.712.377
Registered office: Gabriellestraat 44, 1180 Ukkel
Names & denominations: YAPHARM
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 August 2020
Peppol: Active · Active since 24 Jul 2026
Contact: [email protected]
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗